Insider Cluster (2 insiders) ·Filed Jul 7, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $707K total
Actionable Insight • Neutral

The insider sales are routine and proportionally negligible. No bearish signal. Continue monitoring upcoming earnings and pipeline catalysts for UTHR; this cluster does not suggest adverse developments.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
UTHR ▼ -3.87% at T+60d
NEUTRAL call ✗ call lost -3.87% · α vs SPY -6.07% · entry $563.70 → $541.89
Entry anchored
Jul 6, 03:59 PM ET
via exchange tick
T+1d
-1.66%
call -1.66% · α -1.35%
$554.34
settled 3mo ago
T+5d
-6.57%
call -6.57% · α -7.12%
$526.66
settled 3mo ago
T+20d
-8.41%
call -8.41% · α -9.74%
$516.31
settled 8w ago
T+60d
-3.87%
call -3.87% · α -6.07%
$541.89
settled 2d ago

Price Chart

Loading chart...

Executive Summary

CEO Martine Rothblatt and EVP General Counsel Paul Mahon sold a combined ~$8.5M in open-market shares over a 7-day window, primarily following option exercises. However, the total amount represents only ~0.04% of UTHR's $23.6B market cap — trivial in size. The sales appear routine, driven by option exercise and tax-related liquidity, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$8.5M
Insiders
2

Key Facts

  • CEO Rothblatt sold ~$6.5M in open-market shares, mostly on 2026-07-06 at prices ~$548-$555.
  • EVP Mahon sold ~$2.0M in open-market shares on 2026-07-02 at prices ~$548-$556.
  • Both insiders exercised stock options immediately before or concurrently with the sales — a common liquidity pattern.
  • Total open-market sales of ~$8.5M are 0.036% of UTHR's $23.6B market cap — immaterial.

Financial Impact

Total insider sales of ~$8.5M, <0.04% of market cap — no material financial impact.

dilutioninsider ownership

Risk Factors

  • Further insider selling could emerge if the stock continues to trade near all-time highs.
  • Routine option exercises may continue to generate small insider sales, but no material pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1783433130668
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$571.38 (+14.20%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$571.38 (+14.94%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$571.38 (+13.40%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$571.38 (+12.74%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$571.38 (+17.18%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$571.38 (+17.05%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$571.38 (+10.85%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$571.38 (+8.23%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$571.38 (+10.59%)
Showing 10 of 91

US Market Status

Market Open — Closes in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 7, 2026